Holkova, B., Kmieciak, M., Perkins, E. B., Bose, P., Baz, R. C., Roodman, G. D., . . . Grant, S. (2014). Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. Clin Cancer Res.
Citação norma ChicagoHolkova, Beata, et al. "Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients With Recurrent or Refractory Indolent B-cell Neoplasms." Clin Cancer Res 2014.
ציטוט MLAHolkova, Beata, et al. "Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Non-Hybrid “(Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients With Recurrent or Refractory Indolent B-cell Neoplasms." Clin Cancer Res 2014.